ZYUS LIFE SCIENCES CORP (ZYUS.CA) Stock Price, Forecast & Analysis
Canada - TSX Venture Exchange - TSX-V:ZYUS - CA9899601095 - Common Stock
ZYUS.CA Key Statistics, Chart & Performance
The current stock price of ZYUS.CA is 0.61 CAD. In the past month the price decreased by -12.86%. In the past year, price decreased by -26.51%.
ZYUS.CA Technical Analysis
ZYUS.CA Financial Highlights
Over the last trailing twelve months ZYUS.CA reported a non-GAAP Earnings per Share(EPS) of -0.47. The EPS increased by 13.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -311.03% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ZYUS.CA Forecast & Estimates
5 analysts have analysed ZYUS.CA and the average price target is 1.53 CAD. This implies a price increase of 150.82% is expected in the next year compared to the current price of 0.61.
For the next year, analysts expect an EPS growth of 52.72% and a revenue growth 16.77% for ZYUS.CA
ZYUS.CA Ownership
About ZYUS.CA
Company Profile
ZYUS Life Sciences Corp. is a Canadian-based life sciences company. The company is headquartered in Saskatoon, Saskatchewan. The company went IPO on 2000-10-18. Its lead research program is focused on developing a purified cannabinoid formulation to treat chronic pain due to cancer, musculoskeletal injuries and arthritis. Its lead/first drug product candidate in this program, Trichomylin softgel capsules, is a fixed dose combination of cannabinoids formulated for the treatment of chronic pain in adults. This formulation offers oral administration of highly purified cannabinoids in a controlled dosage. In parallel with the research conducted respecting Trichomylin softgel capsules, it has also identified and commenced research on a second drug candidate. This drug candidate is a cannabinoid-based therapeutic composition for pain management. Both pre-clinical and non-clinical studies have been conducted on this formulation and patent applications have been filed.
Company Info
ZYUS LIFE SCIENCES CORP
407 Downey Road, Unit 204
Saskatoon SASKATCHEWAN CA
Employees: 0
Phone: 13062422357
ZYUS LIFE SCIENCES CORP / ZYUS.CA FAQ
What does ZYUS do?
ZYUS Life Sciences Corp. is a Canadian-based life sciences company. The company is headquartered in Saskatoon, Saskatchewan. The company went IPO on 2000-10-18. Its lead research program is focused on developing a purified cannabinoid formulation to treat chronic pain due to cancer, musculoskeletal injuries and arthritis. Its lead/first drug product candidate in this program, Trichomylin softgel capsules, is a fixed dose combination of cannabinoids formulated for the treatment of chronic pain in adults. This formulation offers oral administration of highly purified cannabinoids in a controlled dosage. In parallel with the research conducted respecting Trichomylin softgel capsules, it has also identified and commenced research on a second drug candidate. This drug candidate is a cannabinoid-based therapeutic composition for pain management. Both pre-clinical and non-clinical studies have been conducted on this formulation and patent applications have been filed.
Can you provide the latest stock price for ZYUS LIFE SCIENCES CORP?
The current stock price of ZYUS.CA is 0.61 CAD.
Does ZYUS LIFE SCIENCES CORP pay dividends?
ZYUS.CA does not pay a dividend.
What is the ChartMill rating of ZYUS LIFE SCIENCES CORP stock?
ZYUS.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the GICS sector and industry of ZYUS stock?
ZYUS LIFE SCIENCES CORP (ZYUS.CA) operates in the Health Care sector and the Pharmaceuticals industry.
How is the valuation of ZYUS LIFE SCIENCES CORP (ZYUS.CA) based on its PE ratio?
ZYUS LIFE SCIENCES CORP (ZYUS.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.47).
What is ZYUS LIFE SCIENCES CORP worth?
ZYUS LIFE SCIENCES CORP (ZYUS.CA) has a market capitalization of 47.59M CAD. This makes ZYUS.CA a Nano Cap stock.